Trials / Withdrawn
WithdrawnNCT05672082
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Center Eugene Marquis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are \[18F\]DPA-714 and 18F-GE180. We hypothesize that \[18F\]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]DPA-714 | Participant received one injection of 200 MBq of \[18F\]DPA-714 |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2025-03-01
- Completion
- 2025-04-01
- First posted
- 2023-01-05
- Last updated
- 2024-02-08
Source: ClinicalTrials.gov record NCT05672082. Inclusion in this directory is not an endorsement.